Sarepta Therapeutics Inc (SRPT)
Gross profit margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 729,585 | 478,303 | 414,033 | 221,562 | 95,172 |
| Revenue | US$ in thousands | 1,243,340 | 933,013 | 701,887 | 540,099 | 380,833 |
| Gross profit margin | 58.68% | 51.26% | 58.99% | 41.02% | 24.99% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $729,585K ÷ $1,243,340K
= 58.68%
The gross profit margin of Sarepta Therapeutics Inc has shown a fluctuating trend over the past five years. In 2019, the gross profit margin was at 24.99%, indicating that the company was generating approximately 24.99 cents of gross profit for every dollar of revenue. This marked a significant increase in 2020, where the margin jumped to 41.02%, suggesting an improvement in the company's ability to generate profits from its core operations.
Subsequently, in 2021, the gross profit margin further increased to 58.99%, reflecting a strong performance in effectively managing its production costs and maximizing profit generation. However, in 2022, there was a slight decline in the gross profit margin to 51.26%, which may indicate potential challenges or increased costs impacting the company's profitability.
The most recent data for 2023 shows a return to a higher gross profit margin of 58.68%, indicating a positive trajectory in profitability. Overall, Sarepta Therapeutics Inc's gross profit margin has demonstrated variability but generally shows an improving trend, with higher margins suggesting better efficiency in production and potentially more effective pricing strategies.
Peer comparison
Dec 31, 2023